In this study, we first discovered that m6A modifications and METTL3 expression were inhibited by chemotherapy; thus, we evaluated the function of METTL3 in regulating HR+HER2− BC progression and drug sensitivity. The gene discussed is ERBB2; the disease is breast cancer.